AARTI PHARMALABS LIMITED
AARTIPHARM · General/Diversified · NSE
₹662
Current Market Price
Under Review— We don’t have enough data to publish a fair value estimate for AARTIPHARM yet. Reason: Data Limited.
Updated just now
YieldIQ Score
—
Piotroski F-Score
4/9
Economic Moat
Narrow
Confidence
13%
ROE
8.2%
Debt/Equity
0.36
WACC
11.1%
Market Cap
₹5,997 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
13.3%
Return on capital employed
EV / EBITDA
17.6×
Enterprise multiple
Debt / EBITDA
1.9×
Leverage vs earnings
Interest Coverage
14.4×
EBIT covers interest
Current Ratio
2.01×
Short-term liquidity
Asset Turnover
0.63×
Revenue per ₹ of assets
Revenue CAGR (3Y)
-2.1%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
Ratio Trends
AARTIPHARM · last 5 annual periods
ROE
8.2%
ROCE
13.3%
Operating Margin
—
Debt / Equity
0.36×
PE
12.9×
EV / EBITDA
7.9×
Historical Financials
AARTIPHARM · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2022 yfinance | 2023 NSE_XBRL | 2024 NSE_XBRL | 2025 yfinance | 2026 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹1192 Cr | ₹1936 Cr | ₹1816 Cr | ₹2115 Cr | ₹1819 Cr | +11.2% |
| EBITDA | ₹198 Cr | ₹344 Cr | ₹391 Cr | ₹474 Cr | ₹384 Cr | +18.0% |
| EBIT | — | ₹282 Cr | ₹318 Cr | — | — | +3.0% |
| PAT | ₹122 Cr | ₹193 Cr | ₹217 Cr | ₹272 Cr | ₹175 Cr | +9.3% |
| EPS (diluted) | — | ₹21.35 | ₹23.93 | — | — | +2.9% |
| CFO | ₹-43.7 Cr | ₹250 Cr | ₹216 Cr | ₹330 Cr | ₹262 Cr | — |
| CapEx | ₹-141 Cr | ₹-120 Cr | ₹-199 Cr | ₹-444 Cr | ₹-448 Cr | — |
| FCF | ₹-185 Cr | ₹130 Cr | ₹17.6 Cr | ₹-114 Cr | ₹-186 Cr | — |
| Total Assets | ₹2040 Cr | ₹2244 Cr | ₹2582 Cr | ₹2906 Cr | ₹3482 Cr | +14.3% |
| Total Debt | ₹341 Cr | ₹215 Cr | ₹285 Cr | ₹421 Cr | ₹754 Cr | +21.9% |
| Shareholders' Equity | ₹1386 Cr | ₹1558 Cr | ₹1757 Cr | ₹1990 Cr | ₹2125 Cr | +11.3% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
AARTIPHARM vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
INNOVACAP INNOVACAP | — | — | Pending | 12.9% | — |
 FDC FDC | — | — | Pending | 11.3% | 18.6× |
 SUVEN SUVEN | — | — | Pending | — | — |
SPARC SPARC | — | — | Pending | 157.9% | — |
SUDEEPPHRM SUDEEPPHRM | — | — | Pending | 28.1% | — |
Click a ticker to view its fair-value analysis.
Dividend History
5 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹9.50/sh
Last payout
2026-02-16
₹1.50
Peak payout
₹2.50
Trailing yield
0.60%
Amounts parsed from NSE subject lines. Percent-of-face-value declarations are converted using the per-ticker face value (defaults to ₹10).
Risk Analysis
Volatility & drawdown
Risk profile of AARTIPHARM →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for AARTIPHARM →
Compare
Head-to-head with peers
Compare AARTIPHARM side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse AARTIPHARMNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.